SEARCH

SEARCH BY CITATION

References

  • 1
    Longley J, Duffy TP, Kohn S. The mast cell and mast cell disease. Journal of the American Academy of Dermatology 1995; 32: 54561.
  • 2
    Sagher F & Even-Paz Z. Mastocytosis and the Mast Cell. Chicago: Year book medical publishers, 1967.
  • 3
    Webb TA, Chin-Yang L, Lung YT. Systemic mast cell disease: A clinical and hematopathologic study of 26 cases. Cancer 1982; 49: 92738.
  • 4
    Travis WD, Chin-Yang L, Bergstralh EJ, Lung YT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine 1988; 67: 34568.
  • 5
    Horan RF & Austen KF. Systemic mastocytosis: Retrospective review of a decades' clinical experience at the Brigham and Womens' hospital. The Journal of Investigative Dermatology 1991; 96: 5s14s.
  • 6
    Dodd NJ & Bond MG. Fatal anaphylaxis in systemic mastocytosis. Journal of Clinical Pathology 1979; 32: 314.
  • 7
    Chamberlain D, Bossaert L, Carli P, et al Guidelines for advanced life support. A statement by the Advanced Life Support working party of the European Resuscitation Council, 1992. Resuscitation 1992; 24: 11121.
  • 8
    Nettleship . Rare forms of urticaria: I Chronic urticaria, leaving brown stains: nearly two years duration. British Medical Journal 1869; 2: 3234.
  • 9
    Li L, Macpherson JJ, Adelstein S, et al Conditioned medium from a cell strain derived from a patient with mastocytosis induces the development of mature human mast cells in vitro from normal human bone marrow. International Archives of Allergy and Immunology 1995; 107: 1424.
  • 10
    Gruchella RS. Southwestern internal medicine conference: mastocytosis: developments during the past decade. The American Journal of the Medical Sciences 1995; 309: 32838.
  • 11
    Demis DJ. The mastocytosis syndrome: clinical and biological studies. Annals of Internal Medicine 1963; 59: 194206.
  • 12
    Roberts LJ, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. New England Journal of Medicine 1980; 303: 14004.
  • 13
    Guillet GY, Dore N, Maleville J. Heparin liberation in Urticaria Pigmentosa. Archives of Dermatology 1982; 118: 5323.
  • 14
    Pollard BJ & Harrison MJ. Anaesthesia for Uncommon Diseases, 1st edn. Oxford: Blackwell Scientific Publications, 1989.
  • 15
    Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. New England Journal of Medicine 1987; 316: 16226.
  • 16
    Schwartz LB, Bradford TR, Rouse C, et al Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. Journal of Clinical Immunology 1994; 14: 190204.
  • 17
    Schwartz LB, Sakai K, Bradford TR, et al The α form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. Journal of Clinical Investigation 1995; 96: 270210.
  • 18
    Frieri M, Alling DW, Metcalfe DD. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorphreniramine and cimetidine in systemic mastocytosis. The American Journal of Medicine 1985; 78: 914.
  • 19
    Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. New England Journal of Medicine 1979; 309: 4659.
  • 20
    Chipman P & Glover WE. Histamine H2 receptors in the human peripheral circulation. British Journal of Pharmacology 1976; 56: 4946.
  • 21
    Roberts LJ, Marney SR, Oates JA. Blockade of the flush associated with metastatic gastric carcinoid by combined histamine H1 and H2 receptor antagonists. New England Journal of Medicine 1979; 300: 2368.
  • 22
    Roberts LJ, Turk JW, Oates JA. Shock syndrome associated with mastocytosis: pharmacological reversal of the acute episode and therapeutic prevention of recurrent attacks. Advances in Shock Research 1982; 8: 14552.
  • 23
    Turk JW, Oates JA, Roberts JL. Intervention with epinephrine in hypotension associated with mastocytosis. Journal of Allergy and Clinical Immunology 1983; 71: 18992.
  • 24
    Fisher M. Treating anaphylaxis with sympathomimetic drugs. British Medical Journal 1992; 305: 11078.
  • 25
    Smith GB, Gusburg RJ, Jordan RH, Kim B. Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis. Anaesthesia 1987; 42: 8617.
  • 26
    Lerno G, Slaats G, Coenen E, Herrogods L, Rolly G. Anaesthetic management of systemic mastocytosis. British Journal of Anaesthesia 1990; 65: 2547.
  • 27
    Scott HW, Parris WCV, Sandidge PC, Oates JA, Roberts LJ. Hazards in operative management of patients with systemic mastocytosis. Annals of Surgery 1983; 197: 50714.
  • 28
    James PD, Krafchik BR, Johnston AE. Cutaneous mastocytosis in children: anaesthetic considerations. Canadian Journal of Anaesthesia 1987; 34: 5224.
  • 29
    Desborough JP, Taylor I, Hattersley A, et al Massive histamine release in a patient with systemic mastocytosis. British Journal of Anaesthesia 1990; 65: 8336.
  • 30
    Hosking MP & Warner MA. Sudden intraoperative hypotension in a patient with asymptomatic urticaria pigmentosa. Anesthesia and Analgesia 1987; 66: 3446.
  • 31
    Association of Anaesthetists of Great Britain and Ireland. Suspected Anaphylactic Reactions Associated with Anaesthesia, 1995.
  • 32
    Rosenbaum KJ & Strobel GE. Anesthetic considerations in mastocytosis. Anesthesiology 1973; 38: 398401.
  • 33
    Katz J, Benumof JL, Kadis LB. Anesthesia and Uncommon Diseases, 3rd edn. WB Saunders Company 1990; 67880.
  • 34
    Stoelting RK, Dierdorf SF, McCammon RL. Anesthesia and Co-Existing Disease, 2nd edn. Churchill Livingstone, 1988; 614.